Primary cutaneous CD30-positive lymphoproliferative disorders

Hematology/Oncology Clinics of North America

Volumn 17, Issue 6, 2003, Pages 1319-1332

  Willemze, Rein ^a   Meijer, Chris J L M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARMUSTINE; CD30 ANTIGEN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; PSORALEN; STEROID; VINCRISTINE;

ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL FEATURE; CLONAL VARIATION; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE CLONE; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; PAPULAR SKIN DISEASE; PATHOGENESIS; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY CUTANEOUS CD30 POSITIVE LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PUVA; REVIEW; SKIN BIOPSY; TREATMENT INDICATION;

EID: 0346367062     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00117-5     Document Type: Review

References (51)

1. Stein H, Foss HD, Dürkop H, et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features. Blood 2000;96:3681-95.
2. Jaffe ES, Harris NL, Stein H, et al, editors. World Health Organization classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2001.
3. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphomas: definition of a new type of cutaneous lymphoma with a favorable prognosis. An European multicenter study on 47 cases. Cancer 1993;71:2097-104.
4. De Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T- or null cell phenotype. Histopathol 1993;23:127-35.
5. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas. A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer (EORTC). Blood 1997;90:354-71.
6. Kadin ME. The spectrum of Ki-1+ cutaneous lymphomas. In: van Vloten WA, editor. Cutaneous lymphoma. Basel (Switzerland): Karger; 1990. p. 132-43.
7. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1) positive lymphoproliferative disorders: A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993;28:973-80.
8. Bekkenk M, Geelen FAMJ, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30-positive lymphoproliferative disorders: long term follow-up data of 219 patients and guidelines for diagnosis and treatment. A report from the Dutch Cutaneous Lymphoma Group. Blood 2000;95:3653-61.
9. Macaulay WL. Lymphomatoid papulosis, a self healing eruption, clinically benign, histologically malignant. Arch Dermatol 1968;97:23-30.
10. Kadin M, Nasu K, Sako D, et al. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's Disease associated antigens. Am J Pathol 1985;119:315-25.
11. Lange Wantzin G, Thomsen K, Nissen NL. Occurrence pfhuman T-cell lymphotropic virus (type I) antibodies in cutaneous T-cell lymphoma. J Am Acad Dermatol 1986;15:598-602.
12. Brice SL, Jester JD, Friednash M, et al. Examination of cutaneous T-cell lymphoma for human herpesviruses by using the polymerase chain reaction. J Cutan Pathol 1993;20:304-7.
13. Kadin ME, Vonderheid EC, Weiss LM. Absence of Epstein-Barr viral RNA in lymphomatoid papulosis. J Pathol 1993;170:145-8.
14. Kempf W, Kadin ME, Kutzner H, et al. Lymphomatoid papulosis and human herpesviruses-PCR-based evaluation for the presence of human herpesvirus 6, 7 and 8 related herpesviruses. J Cutan Pathol 2001;28:29-33.
15. Mori M, Manuelli C, Pimpinelli N, et al. CD30-CD30L interaction in primary cutaneous CD30+ T-cell lymphomas: a clue to the pathophysiology of clinical regression. Blood 1999;94:3077-83.
16. Knaus P, Lindemann D, DeCoteau JF, et al. A dominant inhibitory mutant of the type II transforming growth factor-beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996;16:3480-9.
17. Schieman WP, Pfeifer WM, Levi E, et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in cutaneous T-cell lymphoma. Blood 1999;94:2854-61.
18. Paulli M, Berti E, Boveri E, et al. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998;29:1223-30.
19. Li S, Ross DT, Kadin ME, et al. Comparative genome-scale analysis of gene expression profiles in T-cell lymphoma cells during malignant progression using a complementary DNA microarray. Am J Pathol 2001;158:1231-7.
20. Thomsen K, Lange Wantzin G. Lymphomatoid papulosis. A follow-up study of 30 patients. J Am Acad Dermatol 1987;17:632-6.
21. El-Azhary R, Gibson LE, Kurtin PJ, et al. Lymphomatoid papulosis: a clinical and histopathologic review of 53 cases with leukocyte immunophenotyping, DNA flow cytometry, and T-cell receptor gene rearrangement studies. J Am Acad Dermatol 1994;30:210-8.
22. Banerjee SS, Heald J, Harris M. Twelve cases of Ki-1 positive anaplastic large cell lymphoma of the skin. J Clin Pathol 1991;44:119-25.
23. Krishnan J, Tomaszewski MM, Kao GF. Primary cutaneous CD30-positive anaplastic large cell lymphoma. Report of 27 cases. J Cutan Pathol 1993;20:193-202.
24. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1 positive lymphoproliferative disorders of the skin: clinicopathologic correlation and statistical analysis of 86 cases. J Clin Oncol 1995;13:1343-54.
25. Vergier B, Beylot-Barry M, Pulford K, et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders. Am J Surg Pathol 1998;22:1192-202.
26. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol 1992;126:596-602.
27. Willemze R, Meijer CJLM, Scheffer E, et al. The clinical and histologic spectrum of lymphomatoid papulosis. Br J Dermatol 1982;107:131-44.
28. Beljaards RC, Meijer CJ, Scheffer E, et al. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol 1989;135:1169-78.
29. Kummer JA, Vermeer MH, Dukers DF, et al. Most primary cutaneous CD30-positive tymphopro-lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997;109:636-40.
30. Boulland ML, Wechsler J, Bagot M, et al. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology 2000;36:136-44.
31. DeCouteau JF, Butmarc JR, Kinney MC, et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large cell lymphoma of nodal origin. Blood 1996;87:3437-41.
32. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol 2000;53:445-50.
33. Natkunam Y, Warnke RA, Haghighi B, et al. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Cut Pathol 2000;27:392-9.
34. Bekkenk MW, Kluin PM, Jansen PM, et al. Lymphomatoid papulosis with a natural killer-cell phenotype. Br J Dermatol 2001;145:318-22.
35. Zoi-Toli O, Vermeer MH, de Vries E, et al. Expression of Fas and Fas-1 in primary cutaneous T-cell lymphomas: association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol 2000;143:313-9.
36. Weiss L, Wood G, Trela M, et al. Clonal T-cell populations in lymphomatoid papulosis. N Engl J Med 1986;315:475-9.
37. Steinhoff M, Hummel M, Anagnostopoulos I, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrate a common clonal T-cell origin. Blood 2002;100:578-84.
38. Davis TH, Morton CC, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis and cutaneous T-cell lymphoma derived from a common T-cell clone. N Eng J Med 1992;326:1115-22.
39. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphoma: a distinct clinicopathologic entity with an aggressive clinical behaviour. Am J Pathol 1999;155:483-92.
40. Weenig RH, Ng CS, Pemiciaro C. Subcutaneous panniculitis-like T-cell lymphoma. An elusive case presenting as lipomembraneous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol 2001;23:206-15.
41. Haghighi B, Smoller BR, LeBoit PE, et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular and clinicopathologic study. Mod Pathol 2000;13:502-10.
42. Wu H, Telangh GH, Lessin SR, et al. Mycosis fungoides with CD30-positive cells in the epidermis. Am J Dermatopathol 2000;22:212-6.
43. Weiss LM, Wood GS, Ellison LW, et al. Clonal T-cell populations in pityriasis lichenoides and varioliformis acuta (Mucha-Habermann disease). Am J Pathol 1987;126:417-21.
44. Dereure O, Levi E, Kadin ME. T-cell clonality in pityriasis lichenoides and varioliformis acuta. Arch Dermatol 2000;136:1483-6.
45. Willemze R, Scheffer E. Clinicopathologic studies in pityriasis lichenoides and lymphomatoid papulosis. J Am Acad Dermatol 1985;13:418-28.
46. Varga FJ, Vonderheid EC, Olbricht SM, et al. Immunohistochemical distinction of lymphomatoid papulosis and pityriasis lichenoides and varioliformis acuta. Am J Pathol 1990;136:979-87.
47. Guitart J, Hurt MA. Pleomorphic T-cell infiltrate associated with molluscum contagioum. Am J Dermatopathol 1999;21:178-80.
48. Cesinaro C, Maiorana A. Verruca vulgaris with CD30-positive lymphoid infiltrate: a case report. Am J Dermatopathol 2002;24:260-3.
49. Gallardo F, Toll A, Pujol RM. CD30 antigen expression in cutaneous inflammatory infiltrates of scabies: a dynamic immunophenotypic pattern that should be distinguished from lymphomatoid papulosis. J Cut Pathol 2002;29:368-73.
50. Demierre MF, Goldberg LJ, Kadin ME, et al. Is it lymphoma or lymphomatoid papulosis? J Am Acad Dermatol 1997;36:765-72.
51. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996;34:470-80.